TABLE 3.

Distribution of different pfcrt and pfmdr1 haplotypes in relation to in vivo CQ treatment efficacy and in vitro CQ susceptibility

No. of isolates	pfcrt haplotype (codons 72–76)a	pfmdr1 haplotype (codons 86, 184, 1034, 1042, and 1246)	CQ treatment efficacyb			In vitro CQ responsea
			ACPR	ETF	LTF	S	R
5	CVMNK	NYSND	5			5
37	CVMNK	YYSNY	5	26	6	4	33
11	CVIEK	YYSNY	1	8	2	1	10
4	CVIET	NFSND	2	1	1		4
21	SVMNT	NYSND	17		4	1	20
5	SVMNT	NYSNY	5			1	4
14	SVMNT	YYSND	9	3	2		14
2	CVMNT	NYSNY	2			2
3	CVMNT	YYSNY		3			3
12	CVMNT	NYSND	10	1	1	5	7
12	CVMNT	YYSND	11	1		4	8

^aThe amino acids in bold type represent the mutant codons.

^bACPR, adequate clinical and parasitological response; ETF, early treatment failure; LTF, late treatment failure.

^cS, susceptible (IC₅₀, <100 nM); R, resistant (IC₅₀, >100 nM).